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Age- and Sex-Specific Prevalences of
Diabetes and Impaired Glucose
Regulation in 13 European Cohorts
THE DECODE STUDY GROUP
OBJECTIVE — To report the age- and sex-specific prevalences of diabetes and impaired
glucose regulation (IGR) according to the revised 1999 World Health Organization criteria for
diabetes in Europe.
RESEARCH DESIGN AND METHODS — A total of 13 studies from nine European
countries with 7,680 men and 9,251 women aged 30–89 years were included in the data
analysis.
RESULTS — In most of the study populations, the age-specific prevalences of diabetes were
10% in subjects younger than 60 years and between 10 and 20% at 60–79 years of age. Mean
2-h plasma glucose (2hPG) concentration increased linearly with age, but fasting plasma glucose
(FPG) concentration did not. The increase in the prevalence of undiagnosed diabetes and IGR in
the elderly was mainly a result of the large increase in 2hPG rather than FPG. Diabetes and
impaired fasting glycemia defined by isolated fasting hyperglycemia was more common in men
than in women 30–69 years of age, whereas the prevalence of isolated postload hyperglycemia,
particularly impaired glucose tolerance, was higher in women than in men, especially in the
elderly (individuals 70 years of age). More than half of the diabetes was undiagnosed in
subjects younger than 50 years of age.
CONCLUSIONS — Most European populations have a moderate to low prevalence of dia-
betes and IGR. Diabetes and IGR will be underestimated in Europe, particularly in women and
in elderly men, if diagnoses are based on fasting glucose determination alone.
Diabetes Care 26:61–69, 2003
S tudies on the prevalence of diabetesin the last decades have broadenedour knowledge about the impact of
the disease and guided public health
agencies in planning programs for diabe-
tes care and prevention. There are, how-
ever, still problems related to the
detection, diagnosis, management, and
prevention of diabetes. Recently, the di-
agnostic cutoff value for fasting plasma
glucose (FPG) has been lowered from 7.8
to 7.0 mmol/l (1,2). For epidemiological
studies and for routine clinical practice,
the American Diabetes Association rec-
ommended using fasting glucose testing
alone, and the use of the 2-h oral glucose
tolerance test (OGTT) was not recom-
mend (2), whereas the World Health Or-
ganization (WHO) Consultation still
retained the OGTT (1). The impact of the
changes on the prevalence of diabetes and
on the reclassification of individuals has
been studied in the DECODE (Diabetes
Epidemiology: Collaborative Analysis of
Diagnostic Criteria in Europe) study pop-
ulations (3,4). The results from the
DECODE study (3,4) as well as from
other studies (5–8) have clearly shown
that fasting and 2-h glucose criteria do not
identify the same group of individuals.
Young and obese subjects are more likely
to have diagnostic fasting glucose values
than diagnostic 2-h glucose values (3–
6,8,9).
It has been recognized that the prev-
alence of type 2 diabetes increases with
age, especially in Europe (10,11). How-
ever, in most of the previous epidemio-
logical studies, diabetes has mainly
been defined by the 2-h glucose criteria
alone (11). Whether the increase in
prevalence is a consequence of in-
creased fasting glucose or increased 2-h
glucose concentrations is not known.
Postload hyperglycemia reflects the
acute increase in blood glucose after a
glucose load, whereas fasting glucose is
the glucose concentration after an over-
night fast and reflects mostly hepatic
glucose production. They represent
physiologically different aspects of glu-
cose metabolism and can probably be
influenced differently by the aging pro-
cess. This issue is of importance with
regard to the improvement of diagnosis
and medical care of elderly diabetic pa-
tients. The impact of sex is also an un-
resolved issue (10,11). In this report,
the age- and sex-specific prevalence of
diabetes and impaired glucose regula-
tion (IGR), as well as the age- and sex-
specific prevalence of isolated fasting or
2-h hyperglycemia, was assessed among
some European populations.
RESEARCH DESIGN AND
METHODS
Study population
The study populations and the methods
used to recruit the participants have been
reported in previous DECODE publica-
tions (3,4). Briefly, information on dia-
betic history and data on glucose
measurements at fasting and 2 h after a
standard 75-g OGTT were sent to the Di-
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abetes and Genetic Epidemiology Unit of
the National Public Health Institute in
Helsinki, Finland, for collaborative anal-
yses. The inclusion criteria for the current
study are 1) population-based studies, 2)
studies performed after 1980, 3) studies
including both men and women, 4) at
least two decades of age, and 5) a standard
2-h 75-g OGTT in the morning after an
overnight fast for at least 10 h according
to WHO recommendations (12,13).
A total of 15,606 subjects (7,083 men
and 8,523 women) who had no prior his-
tory of diabetes and 1,325 subjects (597
men and 728 women) who had a prior
history of diabetes, from 13 studies in
nine European countries, met the inclu-
sion criteria for the current data analysis.
The age range was 30–89 years. Demo-
graphic characteristics and information
on the glucose tests for each study cohort
are shown in Table 1. Age ranges and
sample sizes varied between studies, but
the age distribution was similar for men
and women in each cohort. The propor-
tion of female participants was slightly
higher in most of the studies. The partic-
ipation rate in the 2-h OGTT varied from
62 to 100%. Before data analysis, glucose
concentrations of different kinds of blood
specimens were all transformed to plasma
glucose concentrations (APPENDIX).
Classification of glucose
abnormality
Subjects who had a prior history of diabe-
tes were classified as having previously
diagnosed diabetes. Other subjects were
classified according to the 1999 WHO
recommendations for the diagnosis of di-
abetes (1). Classifications of diabetes, im-
paired glucose tolerance (IGT), and
normal glucose tolerance were made ac-
cording to 2-h plasma glucose (2hPG)
concentrations of 11.10, 7.80–11.09,
and 7.80 mmol/l, respectively. FPG
concentrations of7.00, 6.10–6.99, and
6.10 mmol/l classified subjects into di-
abetes, impaired fasting glycemia (IFG),
and normal fasting glucose. IGR accord-
ing to the WHO 1999 recommendations
(1) is either IGT or IFG.
Statistical analysis
Mean FPG and 2hPG concentrations were
calculated for subjects who had no prior
history of diabetes by age-group, for pop-
ulations with at least five 10-year age-
groups. The age- and sex-specific
prevalences of diabetes were calculatedT
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for six 10-year age intervals, from 30 up to
89 years, separately for subjects with and
without diagnosed diabetes. The preva-
lence of diagnosed diabetes (Pkn) was cal-
culated by dividing the number of
diagnosed cases by the total number of
subjects who had responded to the ques-
tions on the prior history of diabetes. Be-
cause there were nonparticipants in the
OGTTs, the prevalence of undiagnosed
diabetes [(undiagnosed cases identified
by the OGTTs/the number of individuals
who attended the OGTTs) (1 Pkn)].
The same rule was applied when calculat-
ing the prevalence of IGR. A 2 test was
used to measure the differences in preva-
lence between men and women.
RESULTS
Age- and sex-specific plasma glucose
concentration
The mean 2hPG concentration rose with
age and increased more after 50 years of
age in each study population (Fig. 1).
Women had a significantly higher mean
2hPG concentration than men in each
age-group except in the fifth decade. The
difference between men and women be-
came larger in subjects older than 70
years of age. In men, the mean FPG con-
centration increased with age up to 69
years of age; thereafter, there was no fur-
ther increase, whereas it rose with age in
women (Fig. 1). The mean FPG concen-
tration was higher in men than in women
at 30–69 years of age; after 70 years of
age, it was higher in women than in men.
Age- and sex-specific prevalence of
diabetes
The age-specific prevalence of diabetes
rose with age up to the seventh and eight
decades in both men and women in each
study population (Table 2, Fig. 2A). In
most of the studies, the prevalence was
10% in subjects younger than 60 years
of age and between 10 and 20% at 60–79
years of age. They were higher in Malta
than in other populations, in each age-
group for both sexes, and the prevalence
of known diabetes was particularly
higher. The prevalence of diabetes was
also higher in elderly Finnish women in
Oulu and in elderly Spanish women in
Guia, compared with most of the other
populations.
As shown in Fig. 2A, the prevalence of
isolated postload hyperglycemia (2hPG
11.1 mmol/l and FPG7.0 mmol/l) in-
creased more with age than isolated fast-
ing hyperglycemia (FPG 7.0 mmol/l
and 2hPG 11.1 mmol/l), especially in
women.
Age- and sex-specific prevalence of
IGR
The prevalence of IGR rose with age in
each study (Table 3 and Fig. 2B). In most
of the study populations, the prevalence
of IGR was 15% at 30–59 years of age
and between 15 and 30% after 60 years of
age. In each age-group, they were higher
in Newcastle in the U.K., Poland, and
Catalonia in Spain, compared with other
populations. The elderly Finnish men and
women in Oulu had the highest preva-
lence of IGR.
The prevalence of IGT increased lin-
early with age, but the prevalence of IFG
Figure 1—Mean fasting (the two lower lines) and 2-h (the two upper lines) plasma glucose concentrations and their 95% CIs (vertical bars) for the
five populations with at least five 10-year age intervals and for all 13 cohorts combined. The three Swedish cohorts were combined as one population,
as were the three Spanish cohorts.
The DECODE Study Group
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Table 2—Prevalences of previously diagnosed and undiagnosed diabetes defined by 2hPG and FPG criteria in men and women in the DECODE
cohorts
Cohort Age (years)
Undiagnosed diabetes (mmol/l)
Diagnosed diabetes Total diabetes
2hPG  11.1 and
FPG  7.0
2hPG  11.1 and
FPG  7.0
2hPG  11.1 and
FPG  7.0
Men Women Men Women Men Women Men Women Men Women
MONICA 1986, Sweden 30–39 1.2 2.6 0 0 2.4 0 0.9 0.5 4.5 3.1
40–49 0 1.3 0 0 0 0 2.5 1.5 2.5 2.8
50–59 0 2.3 1.2 0 1.2 0 5.8 1.4 8.1 3.7
60–64 2.3 5.6 2.3 0 0 0 15 9 19.6 14.6
MONICA 1990, Sweden 30–39 0 1.0 0 1.0 0 0 1.6 0.5 1.6 2.5
40–49 0 0 1.0 0.9 0 0.9 2 1 3.0 2.8
50–59 0 1.7 1.1 0 1.1 0.9 5.5 3.8 7.6 6.4
60–64 0 3.7 3.2 1.8 3.2 0 7.2 5.9 13.6 11.4
MONICA 1994, Sweden 30–39 0 0 1.2 0 0 0 0.6 1.0 1.8 1.0
40–49 1.9 1.9 0.9 1.0 0.9 0 1.5 1.5 5.3 4.4
50–59 1.0 2.8 1.0 0.9 0 0.9 2.6 1.5 4.5 6.1
60–69 3.1 5.7 2.3 1.6 2.3 2.4 6.1 4.5 13.9 14.3
70–74 0 2.4 2.8 0 0 2.4 13.9 8.3 16.7 13.1
MONICA, Finland 40–49 1.2 1.2 1.9 1.8 0 0 1.6 0.8 4.7 3.8
50–59 1.2 0.9 3.6 1.5 1.6 0.7 3.2 3.0 9.6 6.0
60–64 1.2 1.7 2.3 0.9 1.7 0.9 4.1 4.4 9.2 7.8
Oulu, Finland 70–79 7.2 5.3 7.2 8.3 5.4 3.6 17.1 17.2 36.9 34.3
80–89 3.6 9.1 7.1 6.1 0 13.7 0 25.8 10.7 54.6
Hoom, Dutch 50–59 1.5 0.7 2.2 1.8 2.1 0.5 2.2 1.4 8.0 4.4
60–69 1.2 2.5 2.4 1.9 3.4 3.1 3.8 5.0 10.7 12.5
70–77 2.9 4.3 3.5 2.6 5.7 4.7 4.0 8.1 16.0 19.7
Newcastle, U.K. 30–39 0 0 0 0 0 0 0 0 0 0
40–49 1.2 1.2 4.8 0 2.5 1.2 1.3 1.3 9.7 3.7
50–59 1.0 0 6.7 3.0 2.8 2.0 3.1 3.0 13.6 8.0
60–69 1.0 2.1 7.9 6.4 4.9 2.1 3.3 3.3 17.1 13.9
70–76 3.4 6.0 3.4 4.0 3.4 2.0 6.3 0 16.4 12.0
MONICA, Poland 44–49 2.4 0 4.9 2.6 0 0 2.1 0 9.5 2.6
50–59 3.6 3.9 5.4 0 0 1.3 0 2.0 9.0 7.2
60–69 7.4 4.8 2.9 1.6 2.9 0 2.5 11.3 15.7 17.7
70–73 0 10.8 0 0 0 0 5.6 8.3 5.6 19.1
Cremona, Italy 40–49 0 0 0.9 0 0 0.9 3.2 1.2 4.1 2.1
50–59 1.5 0.7 0.8 0 0.4 0.7 5.6 3.7 8.2 5.0
60–69 1.9 1.8 2.4 0.7 1.0 1.1 12.9 9.4 18.2 13.0
70–79 1.2 6.6 0 1.3 4.7 2.6 11.2 10.1 17.1 20.6
80–89 0 3.0 8.5 0 0 3.0 6.7 28.9 15.2 34.9
Viva, Spain 34–39 0 1.1 0 0 0 0 0.4 2.2 0.4 3.3
40–49 1.3 1.5 2.6 0.5 0.7 0.3 0.4 2.6 5.0 4.8
50–59 3.0 1.9 1.9 0.3 0.8 1.6 1.8 3.6 7.5 7.4
60–69 2.5 4.0 1.8 1.5 1.8 0.5 4.3 4.2 10.4 10.3
Catalonia, Spain 30–39 1.5 0.5 0.7 0.5 0 0 1.3 0.3 3.5 1.3
40–49 0 1.4 2.4 1.8 0.6 0 1.7 1.7 4.6 4.8
50–59 2.0 1.2 0.6 0.4 0 0 8.6 7.4 11.3 9.0
60–69 4.0 5.9 1.3 1.5 1.3 0.4 12 17.5 18.6 25.3
70–79 5.3 7.6 0.9 2.6 0 0.9 13.5 19.8 19.6 30.9
80–89 7.3 10.2 2.5 0 0 3.4 11.9 11.1 21.7 24.7
Guia, Spain 30–39 0 0 0 0 0 0 0 0 0 0
40–49 0 0 1.8 1.3 1.8 0 7.0 3.8 10.6 5.2
50–59 3.9 2.8 2.0 1.4 0 2.8 12.2 10.9 18.2 17.9
60–69 3.8 5.1 0 0 3.8 1.3 15.8 19.3 23.4 25.7
70–79 7.1 11.6 0 0 1.7 0 13.3 32.2 22.2 43.8
80–89 0 18.7 0 0 0 6.2 15.6 31.6 15.6 56.5
Malta 30–39 1.4 0.3 1.9 0.7 1.4 0 0.9 4.6 5.6 5.6
40–49 1.1 1.6 2.2 1.2 1.1 0 7.1 4.5 11.6 7.4
50–59 3.2 1.9 2.2 1.1 2.2 1.9 14.1 18.9 21.7 23.8
60–69 0.7 5.4 2.0 1.8 4.7 2.4 25.5 36.3 32.9 45.8
70–79 3.6 7.6 4.8 0 2.4 2.1 32.1 37.6 42.8 47.3
80–87 5.9 8.3 0 4.2 0 8.3 35.3 33.3 41.2 54.2
Total 30–39 0.7 0.6 0.7 0.4 0.6 0* 1.0 1.5 2.9 2.5
40–49 0.8 1.1 2.0 1.0* 0.6 0.2 2.1 1.8 5.4 4.2*
50–59 1.7 1.3 2.3 1.0† 1.3 0.9 4.8 4.6 10.1 7.8*
60–69 2.1 3.6‡ 2.5 1.6 2.5 1.6 8.5 9.3 15.5 16.1
70–79 4.0 6.1* 3.0 2.9 3.4 2.8 12.9 15.4 23.4 27.3*
80–89 3.9 9.2* 3.2 3.1 0 8.6‡ 12.4 22.4* 19.5 43.3‡
Data are %. *P  0.05, †P  0.001, ‡P  0.01, for the difference between men and women.
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did not (Fig. 2B). The concordance be-
tween the two was poor.
Sex difference in prevalence of
diabetes, IFG, and IGT
In most of the study cohorts, the age-
specific prevalences of previously undiag-
nosed diabetes and IGT defined by
isolated postload hyperglycemia were
higher in women than in men, but the
prevalences of undiagnosed diabetes and
IFG diagnosed by isolated fasting hyper-
glycemia were higher in men than in
women (Tables 2 and 3). The sex differ-
ence in the prevalence of undiagnosed di-
abetes and IFG defined by isolated fasting
hyperglycemia was statistically significant
in subjects younger than 70 years of age.
IGT was more prevalent in women than in
men in all age-groups, although signifi-
cantly different only in subjects younger
than 70 years of age (Table 3). Undiag-
nosed diabetes defined by isolated post-
load hyperglycemia was more prevalent
in women than in men after 60 years of
age (Table 2).
The prevalence of previously diag-
nosed diabetes did not differ between
men and women, except in the people
aged 80 years or older, where the preva-
lence was higher in women (Table 2). The
total prevalence of diabetes (Fig. 2A) was
higher in men 40–59 years of age but
Figure 2—Age- and sex-specific preva-
lence of diabetes (A) and IGR (B) for all
studies combined. DMF: Diabetes deter-
mined by FPG 7.0 mmol/l and 2hPG
11.1 mmol/l; DMP: Diabetes determined
by 2hPG 11.1 mmol/l and FPG 7.0
mmol/l; DMF&DMP: Diabetes determined
by FPG 7.0 mmol/l and 2hPG 11.1
mmol/l; Isolated IFG: FPG 6.1–6.9 mmol/l
and 2hPG 7.8 mmol/l; Isolated IGT:
2hPG 7.8 –11.0 mmol/l and FPG 6.1
mmol/l; IFG&IGT: FPG 6.1–6.9 mmol/l
and 2hPG 7.8–11.0 mmol/l. *P  0.05,
**P  0.01, ***P  0.001, for the differ-
ence in the total prevalence between men
and women.
The DECODE Study Group
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Table 3—Prevalences of IGT, IFG, and IGR defined according to 2hPG and FPG criteria (mmol/l) in men and women in the DECODE cohorts
Cohort Age (years)
Isolated IGT Isolated IFG IGT and IFG IGR
2hPG 7.8–11.0 and
FPG  6.1
2hPG  7.8 and
FPG 6.1–6.9
2hPG 7.8–11.0 and
FPG 6.1–6.9 IGT or/and IFG
Men Women Men Women Men Women Men Women
MONICA 1986, Sweden 30–39 4.8 9.2 1.2 1.3 0 0 5.9 10.4
40–49 7.4 7.6 2.4 0 0 1.3 9.8 8.9
50–59 8.1 11.4 1.1 2.3 0 1.2 9.2 14.9
60–64 2.3 11.0 4.6 2.7 2.3 0 9.2 13.7
MONICA 1990, Sweden 30–39 0 3.9 4.5 0 0 1.0 4.5 4.9
40–49 2.0 6.1 14.6 0.9 2.0 0 18.5 7.0
50–59 6.4 6.9 7.6 6.1 0 0.9 14.0 13.9
60–64 0 11.1 12.8 11.1 0 3.7 12.8 25.9
MONICA 1994, Sweden 30–39 2.5 3.9 2.5 0 0 1.0 5.0 4.9
40–49 0.9 2.9 2.8 3.8 3.8 1.9 7.6 8.6
50–59 5.8 9.3 13.6 1.9 4.9 0.0 24.4 11.2
60–69 7.0 13.1 7.0 2.4 3.1 1.6 17.1 17.1
70–74 13.9 16.9 5.6 4.8 0 14.5 19.4 36.2
MONICA, Finland 40–49 4.6 4.9 11.9 6.1 3.4 0.9 20.0 11.8
50–59 7.4 5.3 15.6 4.3 6.6 4.1 29.5 13.7
60–64 7.4 11.6 14.3 4.3 5.2 5.5 26.9 21.4
Oulu, Finland 70–79 18.9 25.4 7.2 7.7 7.2 15.4 33.3 48.5
80–89 35.7 25.7 7.1 6.1 21.4 6.1 64.2 37.9
Hoorn, Dutch 50–59 3.5 3.8 8.8 5.7 2.2 1.4 14.6 10.9
60–69 5.8 9.9 12.9 5.6 3.1 2.5 21.7 18.0
70–77 11.3 11.9 6.8 8.1 3.9 5.1 22.1 25.2
Newcastle, U.K. 30–39 3.0 3.6 11.9 9.1 4.5 1.8 19.4 14.5
40–49 6.1 7.1 15.8 10.7 3.6 2.4 25.5 20.1
50–59 1.9 8.0 31.4 16.0 2.8 6.0 36.1 30.0
60–69 7.9 8.5 13.8 10.6 17.8 5.3 39.6 24.5
70–76 17.1 12.0 11.9 8.0 3.4 14.0 32.3 34.0
MONICA, Poland 44–49 2.4 15.4 14.7 5.1 4.9 7.7 22.0 28.2
50–59 14.3 20.7 16.1 1.3 8.9 3.8 39.3 25.8
60–69 19.2 22.6 10.3 3.2 4.4 4.9 33.9 30.7
70–73 0 16.1 18.9 0 0 10.8 18.9 27.0
Cremona, Italy 40–49 3.1 4.0 1.3 0.4 0.5 0.9 4.9 5.2
50–59 3.4 3.3 7.5 0.7 1.5 1.2 12.4 5.2
60–69 7.3 8.0 3.4 2.5 1.5 2.2 12.2 12.7
70–79 9.5 17.7 2.4 0.6 3.6 1.3 15.5 19.7
80–89 25.5 20.8 0 0 17.0 0 42.5 20.8
Viva, Spain 34–39 3.8 2.1 9.6 2.5 0 1.6 13.3 6.2
40–49 5.2 3.3 4.9 4.0 1.3 1.3 11.4 8.6
50–59 9.0 10.9 4.9 5.1 0.8 1.3 14.7 17.3
60–69 7.9 9.5 4.9 4.0 3.1 2.5 15.9 16.0
Catalonia, Spain 30–39 4.3 7.4 7.2 4.4 1.5 2.5 13.0 14.3
40–49 6.5 9.3 5.9 9.6 3.5 2.8 15.9 21.7
50–59 9.3 12.2 11.3 9.4 5.3 4.9 26.0 26.5
60–69 14.9 13.8 7.9 5.9 5.3 4.9 28.1 24.6
70–79 22.9 17.7 3.5 9.3 7.1 6.7 33.6 33.8
80–89 12.2 30.8 4.9 3.4 7.3 6.8 24.5 41.0
Guia, Spain 30–39 6.3 7.5 6.3 3.8 0 1.3 12.6 12.6
40–49 5.4 11.8 3.5 2.6 1.8 2.6 10.7 17.0
50–59 14.0 19.5 11.9 0.0 3.9 4.2 29.8 23.7
60–69 11.5 15.3 9.6 3.9 3.8 5.1 24.8 24.3
70–79 19.4 11.6 3.6 3.9 3.6 0 26.5 15.5
80–89 16.9 12.5 0 0 13.5 12.5 30.4 24.9
Malta 30–39 0.9 3.0 1.4 2.0 0.9 0.3 3.2 5.2
40–49 2.7 5.4 2.2 2.2 0 0.3 4.9 7.9
50–59 5.9 7.1 1.4 1.5 0 0.4 7.3 8.9
60–69 6.7 8.9 1.3 2.4 3.4 0 11.4 11.3
70–79 10.7 17.2 1.2 3.2 1.2 0 13.2 20.5
80–87 23.6 20.9 0 0 0 4.2 23.6 25.1
Total 30–39 2.9 4.5* 5.2 2.6† 0.8 1.2 8.9 8.3
40–49 4.3 5.8* 6.5 4.4† 2.0 1.4 12.7 11.6†
50–59 6.2 7.5* 10.1 4.6‡ 3.0 2.2 19.2 14.3‡
60–69 8.1 11.1† 8.9 4.7‡ 4.2 3.2 21.2 19.0‡
70–79 15.1 16.9 5.5 5.9 4.3 6.8* 24.8 29.6
80–89 21.3 24.6 3.2 3.1 11.8 5.5 36.2 33.2
Data are %. *P  0.05, †P  0.01, ‡P  0.001, for the difference between men and women.
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lower in men over 70 years of age, com-
pared with women. The similar age and
sex pattern for the prevalence of IGR was
also observed (Fig. 2B).
Proportion of previously
undiagnosed diabetes
The percentage of subjects with undiag-
nosed diabetes varied with age and sex.
For all studies combined, the proportions
of undiagnosed diabetic cases were 0.70,
0.60, 0.50, 0.50, 0.40, and 0.40 in men
and 0.39, 0.58, 0.41, 0.42, 0.43, and 0.48
in women, respectively, at 30–39, 40–
49, 50–59, 60–69, 70–79, and 80–89
years of age. In men, the proportion was
high in young age-groups and decreased
with age, whereas there was not a clear
prevalence pattern with age in women.
CONCLUSIONS — The prevalences
of diabetes and IGT according to the
WHO 1985 criteria have been reported
previously for all of the individual studies
(14–24), but the prevalence of diabetes
and IGR according to the revised WHO
1999 criteria (1) have not been fully re-
ported. In the current article, the age- and
sex-specific prevalences of diabetes and
IGR as well as their components accord-
ing to the revised diagnostic criteria were
investigated in each of the individual
studies and in all studies combined. We
found that the 2hPG concentration in-
creased linearly with age, but the FPG
concentration did not. The increase in the
prevalence of undiagnosed diabetes and
IGR in the elderly population resulted
mainly from the large increase in postload
hyperglycemia rather than fasting hyper-
glycemia. In addition, we found that there
was a distinct sex difference in the preva-
lence of diabetes, IFG, and IGT. Undiag-
nosed diabetes and IFG defined by
isolated fasting hyperglycemia was more
common in men than in women at 30–69
years of age, whereas the prevalence of
isolated postload hyperglycemia was
higher in women than in men and was
particularly higher in the elderly popula-
tion (70 years of age).
The finding that postload hyperglyce-
mia was more prevalent in the elderly was
consistent with a recent report from the
Third National Health and Nutrition Ex-
amination Survey (NHANES III) (25). In
that report, however, men and women
were not studied separately. Our study
further revealed that postload hypergly-
cemia, particularly IGT, was also more
prevalent in women of all ages than in
men. This finding is consistent with a pre-
vious report that there are, worldwide,
more women than men with IGT (11).
Therefore, the prevalence of undiagnosed
diabetes and IGR would be underesti-
mated to a large extent in Europe, espe-
cially in female and elderly populations, if
fasting glucose determination alone
would be used, whereas the primary pur-
pose of a population-based screening pro-
gram for diabetes is to detect previously
undiagnosed diabetes and IGR.
The prevalence of previously undiag-
nosed diabetes, according to a FPG level
of 7.0 mmol/l alone, for U.S. adults
aged 20 years was estimated in the
NHANES III (26). At a comparable age
range of 40–59 years, the prevalence of
undiagnosed diabetes according to the
same fasting glucose criteria was lower in
most of the female populations and in
about half of the male European popula-
tions, compared with the U.S. non-
Hispanic white population, but they were
all lower than those of Mexican American
subjects.
Age- and sex-specific prevalences of
diabetes (known plus unknown cases de-
fined according to 2hPG 11.1 mmol/l)
in selected populations worldwide have
been assembled using aggregate data and
were reported by King et al. in 1993 (11).
However, in that report, only two small
European studies from Poland and Fin-
land were included, and the old WHO
1985 criteria were used (13). In the cur-
rent study, age- and sex-specific preva-
lences of diabetes and IGR according to
the recently revised WHO 1999 diagnos-
tic criteria were reported for 13 European
cohorts based on the individual data. At
comparable age ranges of 30–69 years,
the prevalences of diabetes, estimated us-
ing the same 2-h glucose criteria, in most
of the European populations were lower
than most of the other populations world-
wide, but higher than those in the Bantu
in Tanzania and the Chinese in Da Qing
(11). About half of the male European
populations had higher and half had
lower prevalences of diabetes than U.S.
non-Hispanic men, whereas U.S. non-
Hispanic white women had higher preva-
lences than most of their female European
counterparts in all age-groups. Europeans
have a moderate to low prevalence of di-
abetes compared with most of the other
racial and ethnic groups worldwide
where age- and sex-specific prevalences
of diabetes have been reported.
The ratio of prevalences of glucose
abnormality between men and women
has been estimated in many studies, but
so far there has been no consistent trend
(11,26). The previous WHO estimate
(11) was based on aggregate data with
age-standardized rates rather than on in-
dividual subject data with age-specific
rates. The major limitation of using aggre-
gate data is that detailed analysis using the
same strategy cannot be made. In addi-
tion, an age-standardized estimate does
not represent the true population preva-
lence because it depends not only on the
actual age-specific rates in the study sam-
ple but also on the age distribution of the
chosen standard population. Our study
showed a clear sex pattern in the preva-
lence of postload hyperglycemia and the
prevalence of fasting hyperglycemia. This
pattern was similar to the sex patterns of
the population distributions of age-
specific FPG and 2hPG concentrations.
The findings may be important for plan-
ning treatment strategy, designing screen-
ing programs, and improving diabetes
care.
The DECODE study is based on col-
laborative analysis of the existing popula-
tion-based databases. It is an economic
and efficient way to maximize and opti-
mize the use of survey databases. During
the data analysis, the same diagnostic cri-
teria and strategy could be used in all
studies, and thus, results could be com-
pared directly between studies. However,
because the individual surveys have been
carried out independently, there were dif-
ferences in study design, participation
rate, and classification of known diabetes
and no centralized glucose assays, despite
the application of uniform inclusion cri-
teria. Nevertheless, there were many sim-
ilarities between studies, such as the
number of hours of fasting, the time for
blood sampling, and the method for glu-
cose assay. Moreover, the findings were
also homogeneous among the DECODE
populations in terms of the age-specific
glucose concentrations and the sex differ-
ence in prevalence of fasting and postload
hyperglycemia. This suggests the findings
are valid.
In conclusion, the prevalence of dia-
betes and IGR in Europe was moderate to
low compared with other worldwide re-
ports. The prevalence of isolated postload
hyperglycemia (diabetes and IGT) in-
The DECODE Study Group
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creased with age, but the prevalence of
isolated fasting hyperglycemia (diabetes
and IFG) did not. The former was more
common in women of all ages and in el-
derly men, and the latter more prevalent
in young and middle-aged men. Diabetes
and IGR will be underestimated in Eu-
rope, particularly in women and in el-
derly men, if diagnosis of diabetes is based
on FPG determination alone.
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